UroGen Pharma Ltd. URGN
Set alert
34.47 USD +0.11 +0.31%
As of Nov 3, 1:26 PM ET
34.00 Day range 34.97
16.50 52-week range 50.81
- YTD
- +47.16%
- 1 year
- +67.14%
- Open
- 34.50
- Prev close
- 34.36
- Mkt cap
- 1.69B
- Vol
- 596.41K
- Avg vol
- 964.75K
- EPS
- -1.97
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 34.00
- High
- 34.97
- Forward P/E
- 12.45
- Beta
- 1.64
- Short ratio
- 5.87
- Inst. own
- 98.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 40.44
- 200-d avg
- 31.31
- 1y target
- 60.00
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 60.00 +74.1% upside
Now 34.47
- Target (low)
- 48.00
- Target (mean)
- 60.00
- Target (high)
- 75.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy1
- Buy6
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.09143 | -0.07 – 0.19 | -0.69 | +113.3% | 89.83M | +226.8% | 7 |
| Next quarter | 0.39 | -0.01 – 0.77 | -0.53 | +173.6% | 107.29M | +183.6% | 7 |
| Current year | -0.24286 | -0.83 – 0.20 | -3.19 | +92.4% | 320.52M | +191.9% | 7 |
| Next year | 2.59 | 1.05 – 5.19 | -0.24286 | +1165.3% | 522.84M | +63.1% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 5, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jul 21, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 16, 2026 | Oppenheimer | Maintained | Outperform | Outperformer |
| Jun 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 11, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 7, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 31, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Mar 2, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Jan 23, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Aug 19, 2025 | Piper Sandler | Initiated | — | Overweight |
| Aug 11, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 7, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Aug 5, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Jul 8, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 7, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Jun 16, 2025 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Jun 13, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Jun 13, 2025 | Guggenheim | Maintained | Buy | Buy |
| Jun 13, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Jun 12, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Jun 3, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| May 23, 2025 | Guggenheim | Maintained | Buy | Buy |
| May 22, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 22, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| May 13, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 12, 2025 | D. Boral Capital | Maintained | Buy | Buy |